ETS6103 (Major Depressive Disorder) - Forecast and Market Analysis to 2023
|出版日期||內容資訊||英文 59 Pages
|ETS6103 (重度憂鬱症)-預測與市場分析 ETS6103 (Major Depressive Disorder) - Forecast and Market Analysis to 2023|
|出版日期: 2014年05月30日||內容資訊: 英文 59 Pages||
Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded and competitive market, with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli Lilly's Cymbalta, and Otsuka/BMS's Abilify, along with the recent launch of the multimodal antidepressant, Lundbeck/Takeda's Brintellix, in January 2014, and the potential introduction of seven promising late-stage pipeline products into the market during the forecast period, from 2013 to 2023.
ETS6103 is being developed by e-Therapeutics for the treatment of MDD in patients who have not responded adequately to first-line therapy with an SSRI. ETS6103 is a controlled-release formulation of tramadol (e-Therapeutics, press release, October 31, 2013). Tramadol is a centrally acting synthetic analgesic compound, which is indicated for the treatment of moderate-to-severe pain.